Your browser doesn't support javascript.
loading
Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.
Purshouse, Karin; Schuh, Anna; Fairfax, Benjamin P; Knight, Sam; Antoniou, Pavlos; Dreau, Helene; Popitsch, Niko; Gatter, Kevin; Roberts, Ian; Browning, Lisa; Traill, Zoe; Kerr, David; Verrill, Clare; Tuthill, Mark; Taylor, Jenny C; Protheroe, Andrew.
Afiliação
  • Purshouse K; Oxford Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Schuh A; Oxford National Institute for Health Research, Biomedical Research Centre/NHS Translational Diagnostics Centre, The Joint Research Office, The Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Fairfax BP; Oxford Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Knight S; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom.
  • Antoniou P; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom.
  • Dreau H; Oxford National Institute for Health Research, Biomedical Research Centre/NHS Translational Diagnostics Centre, The Joint Research Office, The Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Popitsch N; Oxford National Institute for Health Research, Biomedical Research Centre/NHS Translational Diagnostics Centre, The Joint Research Office, The Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Gatter K; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom.
  • Roberts I; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
  • Browning L; Molecular Oncology and Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom.
  • Traill Z; Department of Cellular Pathology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, United Kingdom.
  • Kerr D; Department of Radiology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, United Kingdom.
  • Verrill C; Oxford Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Tuthill M; Department of Cellular Pathology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, United Kingdom.
  • Taylor JC; Oxford Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
  • Protheroe A; Oxford National Institute for Health Research, Biomedical Research Centre/NHS Translational Diagnostics Centre, The Joint Research Office, The Churchill Hospital, Headington, Oxford OX3 7LE, United Kingdom.
Cold Spring Harb Mol Case Stud ; 3(3): a001362, 2017 05.
Article em En | MEDLINE | ID: mdl-28487881
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteína BRCA2 Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteína BRCA2 Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article